BioSpace News Archive

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that it has been named one of the Top Places to Work in Massachusetts in The Boston Globe’s 14th annual employee-based survey.

Surface Oncology today announced that new data from the ongoing Phase 1 study of SRF617, an antibody targeting CD39, will be presented in a scientific poster at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO), to be held virtually from December 8-11, 2021.

Ambys Medicines, a company aiming to be the leader in cell therapy for severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced the appointment of Markus Grompe, M.D., as the company’s Chief Scientific Officer.

Halberd Corporation (OTC PINK: HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).

IncellDx today announced Todd Pollard has joined its executive leadership team as Chief Operating Officer.

Syapse® presented five abstracts at Virtual ISPOR Europe 2021 , the leading global conference for health economics and outcomes research (HEOR), held last week.

Tevogen Bio, a clinical stage biotechnology company, announces the appointments of Dr. Lindee Goh who leads Tapestry Networks healthcare practice and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center in Tennessee, to its Innovation and Public Health Advisory Council.

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Merck’s Keytruda (pembrolizumab) to include patients with Stage IIB and IIC melanoma.

Adagene Inc. announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021.

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company’s compound, GZR18, to improve the management of type 2 diabetes mellitus.